Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 20/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 20/20 | 0.68 |
| ▸ | DRD2 | P14416 | 16/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2822551 | 0.91 | DRD3 (0.75) | DRD3KCNH2DRD2CYP1A2 | |
| Hydrochloric Acid SCHEMBL2819910 | 0.91 | DRD3 (0.74) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL2819231 | 0.87 | DRD3 (0.68) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL2822365 | 0.87 | DRD3 (0.68) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL2822364 | 0.87 | DRD3 (0.68) | DRD3KCNH2DRD2CYP1A2 | |
| Hydrochloric Acid SCHEMBL2822299 | 0.86 | DRD3 (0.67) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL378352 | 0.81 | DRD3 (1.00) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL2819702 | 0.80 | DRD3 (0.50) | DRD3KCNH2DRD2CYP1A2 | |
| Hydrochloric Acid SCHEMBL397107 | 0.80 | DRD3 (0.98) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL2820695 | 0.80 | DRD3 (0.57) | DRD3KCNH2DRD2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891057-B1 | AZABICYCLO[3.1.0]HEXANE DERIVAIVES AS DOPAMIN D3 RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2010-10-27 | — | — | EP | claimed |
| US-20090326011-A1 | AZAB I CYCLO [3 . 1 . 0] HEXANE DERIVATIVES AS DOPAMIN D3 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | claimed |
| EP-1891057-A1 | AZAB I CYCLO [3 . 1 . 0] HEXANE DERIVATIVES AS DOPAMIN D3 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-02-27 | — | — | EP | claimed |
| WO-2006133946-A1 | AZAB I CYCLO [3 . 1 . 0] HEXANE DERIVATIVES AS DOPAMIN D3 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-12-21 | — | — | WO | claimed |
| EP-1891057-B1 | AZABICYCLO[3.1.0]HEXANE DERIVAIVES AS DOPAMIN D3 RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2010-10-27 | — | — | EP | disclosed |
| US-20090326011-A1 | AZAB I CYCLO [3 . 1 . 0] HEXANE DERIVATIVES AS DOPAMIN D3 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090326011-A1 | AZAB I CYCLO [3 . 1 . 0] HEXANE DERIVATIVES AS DOPAMIN D3 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090326011-A1 | AZAB I CYCLO [3 . 1 . 0] HEXANE DERIVATIVES AS DOPAMIN D3 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| EP-1891057-A1 | AZAB I CYCLO [3 . 1 . 0] HEXANE DERIVATIVES AS DOPAMIN D3 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006133946-A1 | AZAB I CYCLO [3 . 1 . 0] HEXANE DERIVATIVES AS DOPAMIN D3 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326011-A1 | AZAB I CYCLO [3 . 1 . 0] HEXANE DERIVATIVES AS DOPAMIN D3 RECEPTOR MODULATORS | CHRNB3, DRD2, DRD3 | DRD3 3/4885KCNH2 3734/4885DRD2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.